A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.
CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...
For people with lung or pancreatic cancer driven by changes in the KRAS gene, research presented at the 2026 European Society ...
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to ...
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, ...
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and ...
Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution ...
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results